irofulven has been researched along with Carcinoma, Anaplastic in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Comisso, M; Koeppel, F; Larsen, AK; Poindessous, V; Raymond, E; Waters, SJ | 1 |
Cvitkovic, E; Koeppel, F; Larsen, AK; Poindessous, V; Raymond, E; Waters, SJ | 1 |
Estes, LA; Kelner, MJ; McMorris, TC; Rojas, RJ; Suthipinijtham, P | 1 |
3 other study(ies) available for irofulven and Carcinoma, Anaplastic
Article | Year |
---|---|
Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Carcinoma; Cell Line, Tumor; Cisplatin; Culture Media; Dioxoles; Drug Resistance, Neoplasm; Epithelial Cells; Glutamate-Cysteine Ligase; Glutathione Transferase; Humans; Isoquinolines; Models, Chemical; Plant Extracts; Polycyclic Sesquiterpenes; rho GTP-Binding Proteins; Sesquiterpenes; Tetrahydroisoquinolines; Time Factors; Trabectedin; Tumor Suppressor Protein p53 | 2003 |
Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cisplatin; Coloring Agents; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Inhibitory Concentration 50; Models, Chemical; Ovarian Neoplasms; Sesquiterpenes; Tetrazolium Salts; Thiazoles | 2003 |
Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
Topics: Altretamine; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; DNA Damage; DNA, Neoplasm; Drug Synergism; Female; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Organoplatinum Compounds; Random Allocation; Sesquiterpenes; Transcription, Genetic; Xenograft Model Antitumor Assays | 2008 |